Ugint Co Ltd (195990) - Net Assets
Based on the latest financial reports, Ugint Co Ltd (195990) has net assets worth ₩56.88 Billion KRW (≈ $38.55 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩79.19 Billion ≈ $53.66 Million USD) and total liabilities (₩22.30 Billion ≈ $15.11 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Ugint Co Ltd (195990) strategic investment index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩56.88 Billion |
| % of Total Assets | 71.83% |
| Annual Growth Rate | -1.91% |
| 5-Year Change | -60.72% |
| 10-Year Change | -50.73% |
| Growth Volatility | 24.35 |
Ugint Co Ltd - Net Assets Trend (2014–2025)
This chart illustrates how Ugint Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 195990 market cap overview.
Annual Net Assets for Ugint Co Ltd (2014–2025)
The table below shows the annual net assets of Ugint Co Ltd from 2014 to 2025. Also explore Ugint Co Ltd (195990) equity growth momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩54.03 Billion ≈ $36.61 Million |
-49.98% |
| 2024-12-31 | ₩108.01 Billion ≈ $73.20 Million |
-11.71% |
| 2023-12-31 | ₩122.34 Billion ≈ $82.91 Million |
-12.74% |
| 2022-12-31 | ₩140.20 Billion ≈ $95.01 Million |
+1.93% |
| 2021-12-31 | ₩137.54 Billion ≈ $93.21 Million |
-1.12% |
| 2020-12-31 | ₩139.10 Billion ≈ $94.27 Million |
+17.45% |
| 2019-12-31 | ₩118.43 Billion ≈ $80.26 Million |
+10.81% |
| 2018-12-31 | ₩106.88 Billion ≈ $72.43 Million |
+9.47% |
| 2017-12-31 | ₩97.64 Billion ≈ $66.17 Million |
-10.96% |
| 2016-12-31 | ₩109.66 Billion ≈ $74.31 Million |
+5.60% |
| 2015-12-31 | ₩103.84 Billion ≈ $70.37 Million |
+55.47% |
| 2014-12-31 | ₩66.79 Billion ≈ $45.26 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Ugint Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 466.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩231.51 Billion | 428.50% |
| Total Equity | ₩54.03 Billion | 100.00% |
Ugint Co Ltd Competitors by Market Cap
The table below lists competitors of Ugint Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bytes Technology Ltd
LSE:BYIT
|
$12.96 Million |
|
Impedimed Ltd
AU:IPD
|
$12.96 Million |
|
SILVER DOLLAR RES
F:4YW
|
$12.96 Million |
|
Nosa Med AB
ST:NOSA
|
$12.96 Million |
|
Pluri Inc.
NASDAQ:PLUR
|
$12.95 Million |
|
Thunderful Group AB
ST:THUNDR
|
$12.95 Million |
|
Glen Burnie Bancorp
NASDAQ:GLBZ
|
$12.94 Million |
|
Mcphersons Ltd
AU:MCP
|
$12.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ugint Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 108,011,934,960 to 54,028,843,070, a change of -53,983,091,890 (-50.0%).
- Net loss of 48,919,928,970 reduced equity.
- Other factors decreased equity by 5,063,162,920.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-48.92 Billion | -90.54% |
| Other Changes | ₩-5.06 Billion | -9.37% |
| Total Change | ₩- | -49.98% |
Book Value vs Market Value Analysis
This analysis compares Ugint Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.31x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.79x to 0.31x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1492.02 | ₩1174.00 | x |
| 2017-12-31 | ₩1323.21 | ₩1174.00 | x |
| 2018-12-31 | ₩1085.49 | ₩1174.00 | x |
| 2019-12-31 | ₩670.01 | ₩1174.00 | x |
| 2020-12-31 | ₩553.15 | ₩1174.00 | x |
| 2021-12-31 | ₩528.59 | ₩1174.00 | x |
| 2022-12-31 | ₩512.25 | ₩1174.00 | x |
| 2023-12-31 | ₩429.74 | ₩1174.00 | x |
| 2024-12-31 | ₩379.40 | ₩1174.00 | x |
| 2025-12-31 | ₩3795.65 | ₩1174.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ugint Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -90.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -153.24%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.38x
- Recent ROE (-90.54%) is below the historical average (-16.43%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 22.29% | 17.15% | 0.72x | 1.80x | ₩8.13 Billion |
| 2015 | 14.47% | 19.48% | 0.56x | 1.32x | ₩4.64 Billion |
| 2016 | 0.02% | 0.04% | 0.30x | 1.52x | ₩-10.95 Billion |
| 2017 | -11.91% | -25.30% | 0.27x | 1.76x | ₩-21.39 Billion |
| 2018 | -10.35% | -18.79% | 0.33x | 1.65x | ₩-21.75 Billion |
| 2019 | -30.14% | -111.79% | 0.17x | 1.60x | ₩-47.54 Billion |
| 2020 | -42.40% | -119.66% | 0.30x | 1.19x | ₩-72.88 Billion |
| 2021 | -7.29% | -30.47% | 0.20x | 1.22x | ₩-23.78 Billion |
| 2022 | -5.81% | -36.83% | 0.14x | 1.12x | ₩-22.16 Billion |
| 2023 | -21.04% | -101.44% | 0.18x | 1.16x | ₩-37.98 Billion |
| 2024 | -14.47% | -49.36% | 0.22x | 1.31x | ₩-26.43 Billion |
| 2025 | -90.54% | -153.24% | 0.43x | 1.38x | ₩-54.32 Billion |
Industry Comparison
This section compares Ugint Co Ltd's net assets metrics with peer companies in the Specialty Industrial Machinery industry.
Industry Context
- Industry: Specialty Industrial Machinery
- Average net assets among peers: $162,529,814,432
- Average return on equity (ROE) among peers: 4.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ugint Co Ltd (195990) | ₩56.88 Billion | 22.29% | 0.39x | $12.95 Million |
| Hwacheon Mac (000850) | $209.21 Billion | 12.92% | 0.49x | $58.97 Million |
| Daidong Elec (008110) | $116.48 Billion | 10.01% | 0.24x | $71.25 Million |
| Booster Co. Ltd (008470) | $78.71 Billion | -1.57% | 0.22x | $18.75 Million |
| Simpac (009160) | $435.03 Billion | 15.91% | 0.57x | $174.93 Million |
| Kyung Dong Navien Co Ltd (009450) | $256.51 Billion | 10.30% | 0.96x | $600.41 Million |
| Korea Refract (010040) | $129.43 Billion | 5.52% | 0.58x | $37.46 Million |
| Woojin I&S Co Ltd (010400) | $97.09 Billion | -3.31% | 0.18x | $18.86 Million |
| Hwacheon Machi (010660) | $123.14 Billion | 0.47% | 0.27x | $46.59 Million |
| Han Shin Mach (011700) | $77.29 Billion | 7.98% | 0.23x | $55.79 Million |
| STX Corporation (011810) | $102.41 Billion | -13.24% | 6.24x | $74.11 Million |
About Ugint Co Ltd
RootK Co., Ltd. manufactures and sells machine tools and biotechnology products in South Korea and internationally. It offers tapping centers, spindle machines, machining and turning centers, and machining centers with long table. Additionally, It also offers bispecific antibody therapeutics for ophthalmic and oncology indications, including anti-VEGF/ANG2, anti-HER2/CD3, anti-GPC3/CD3, and anti-… Read more